Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / Innovent Biologics, Inc.

2025 · Licensing/Option · $11.4B · Complete

Takeda licensed global rights (ex-Greater China) to two late-stage oncology candidates from Innovent plus option to license IBI3001. Innovent receives $1.2B upfront (including $100M equity investment) and up to $10.2B in milestones, total up to $11.4B. Largest China-outbound biopharma licensing deal of 2025. Closed December 4, 2025.

Key facts

• Announced Oct 21, 2025
• Closed Dec 04, 2025
• Deal value $11.4B
• Deal type Licensing/Option
• Therapeutic area NSCLC, colorectal, gastric, pancreatic cancer
• Indications NSCLC, colorectal, gastric, pancreatic cancer
• Key assets IBI363, IBI343 (and IBI3001 option)
• Mechanism Next-generation IO backbone and ADC molecules

← Browse all deals  ·  How we score deals